Стадирование опухолевого процесса и формирование групп риска у детей, больных герминогенными опухолями яичников
Стадирование опухолевого процесса и формирование групп риска у детей, больных герминогенными опухолями яичников
Нечушкина И.В., Нечушкина В.М., Бойченко Е.И. и др. Стадирование опухолевого процесса и формирование групп риска у детей, больных герминогенными опухолями яичников. Современная Онкология. 2019; 21 (1): 36–39. DOI: 10.26442/18151434.2019.1.190251
________________________________________________
Nechushkina I.V., Nechushkina V.M., Boychenko E.I. et al. Staging and identification of risk groups in pediatric germ cell ovarian tumors. Journal of Modern Oncology. 2019; 21 (1): 36–39. DOI: 10.26442/18151434.2019.1.190251
Стадирование опухолевого процесса и формирование групп риска у детей, больных герминогенными опухолями яичников
Нечушкина И.В., Нечушкина В.М., Бойченко Е.И. и др. Стадирование опухолевого процесса и формирование групп риска у детей, больных герминогенными опухолями яичников. Современная Онкология. 2019; 21 (1): 36–39. DOI: 10.26442/18151434.2019.1.190251
________________________________________________
Nechushkina I.V., Nechushkina V.M., Boychenko E.I. et al. Staging and identification of risk groups in pediatric germ cell ovarian tumors. Journal of Modern Oncology. 2019; 21 (1): 36–39. DOI: 10.26442/18151434.2019.1.190251
В обзоре литературы представлены данные о стадировании герминогенных опухолей яичников у детей, а также формировании групп риска. Определение стадии процесса и формирование групп риска значительно отличаются от принятых во взрослой онкологии.
Data on the staging and identification of the risk groups in pediatric germ cell ovarian tumors are presented in the review of the literature. Both staging and risk group identification are significantly different from accepted for adult patients.
1. Palenzuela G, Martin E, Meunier A et al. Comprehensive staging allows for excellent out-come in patients with localized malignant germ cell tumor ovary. Ann Surg 2008; 248: 836–41.
2. Liu Q, Ding X, Yang J et al. The signification of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol 2013; 131 (3): 551–4.
3. Billmire DF, Cullen JW, Frederick JR et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Chidren’s Oncology Group. J Clin Oncol 2014; 32 (5): 465–70.
4. Billmire D, Vinocur C, Rescorla F et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39 (3): 424–9.
5. Kurman RJ, Norris HJ. Endodermal sinus tumor of ovary. A clinical and pathologic analysis of 71 cases. Cancer 1976; 38 (6): 2404–19.
6. Cushing B, Giller R, Cullen JW et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study – Pediatric Oncology Group 9049 and Children Cancer Group 8882. J Clin Oncol 2004; 22: 2691–700.
7. Palenzuela G, Martin E, Meunier A et al. Comprehensive staging allows for excellent out-come in patients with localized malignant germ cell tumor ovary. Ann Surg 2008; 248: 836–41.
8. Буланов А.А., Трякин А.А., Тюляндин С.А. Лечение герминогенных опухолей ранних (I, IIA, B) стадий. Практическая онкология. 2006; 7 (1): 24–9.
[Bulanov A.A., Triakin A.A., Tiuliandin S.A. Lechenie germinogennykh opukholei rannikh (I, IIA, B) stadii. Prakticheskaia onkologiia. 2006; 7 (1): 24–9 (in Russian).]
9. Тюляндин С.А. Герминогенные опухоли яичников. Практическая онкология. 2006; 7 (1): 52–61.
[Tiuliandin S.A. Germinogennye opukholi iaichnikov. Prakticheskaia onkologiia. 2006; 7 (1): 52–61 (in Russian).]
10. Oltmann SC, Garcia NM, Barber R et al. Pediatric ovarian malignancies: how efficacious are current staging practices? J Pediatr Surg 2010; 45 (6): 1096–102.
11. Frazier AL, Rumcheva P, Olson T et al. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008; 50 (4): 746–51.
12. Lee KH, Lee IH, Kim BG et al. Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women; A Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009; 19 (1): 84–7.
13. Zanagnolo V, Sartori E, Galleri G et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;
25 (3): 315–20.
14. Panteli C, Curry J, Kiely E et al. Ovarian germ cell tumors: a 17-year study in a single unit. Eur J Pediatr Surg 2009; 19: 96–100.
________________________________________________
1. Palenzuela G, Martin E, Meunier A et al. Comprehensive staging allows for excellent out-come in patients with localized malignant germ cell tumor ovary. Ann Surg 2008; 248: 836–41.
2. Liu Q, Ding X, Yang J et al. The signification of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol 2013; 131 (3): 551–4.
3. Billmire DF, Cullen JW, Frederick JR et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Chidren’s Oncology Group. J Clin Oncol 2014; 32 (5): 465–70.
4. Billmire D, Vinocur C, Rescorla F et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39 (3): 424–9.
5. Kurman RJ, Norris HJ. Endodermal sinus tumor of ovary. A clinical and pathologic analysis of 71 cases. Cancer 1976; 38 (6): 2404–19.
6. Cushing B, Giller R, Cullen JW et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study – Pediatric Oncology Group 9049 and Children Cancer Group 8882. J Clin Oncol 2004; 22: 2691–700.
7. Palenzuela G, Martin E, Meunier A et al. Comprehensive staging allows for excellent out-come in patients with localized malignant germ cell tumor ovary. Ann Surg 2008; 248: 836–41.
8. Bulanov A.A., Triakin A.A., Tiuliandin S.A. Lechenie germinogennykh opukholei rannikh (I, IIA, B) stadii. Prakticheskaia onkologiia. 2006; 7 (1): 24–9 (in Russian).
9. Tiuliandin S.A. Germinogennye opukholi iaichnikov. Prakticheskaia onkologiia. 2006; 7 (1): 52–61 (in Russian).
10. Oltmann SC, Garcia NM, Barber R et al. Pediatric ovarian malignancies: how efficacious are current staging practices? J Pediatr Surg 2010; 45 (6): 1096–102.
11. Frazier AL, Rumcheva P, Olson T et al. Application of the adult international germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008; 50 (4): 746–51.
12. Lee KH, Lee IH, Kim BG et al. Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women; A Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009; 19 (1): 84–7.
13. Zanagnolo V, Sartori E, Galleri G et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;
25 (3): 315–20.
14. Panteli C, Curry J, Kiely E et al. Ovarian germ cell tumors: a 17-year study in a single unit. Eur J Pediatr Surg 2009; 19: 96–100.
1 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2;
3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*ivnechushkina@mail.ru
________________________________________________
Innesa V. Nechushkina*1,2, Valentina M. Nechushkina1,3, Elena I. Boychenko1,2, Natal'ia A. Susuleva1,2, Anatolii P. Kazantsev1, Polad A. Kerimov1, Mikhail I. Nechushkin1, Mikhail A. Rubansky1
1 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 23, Kashirskoe h., Moscow, 115478, Russian Federation;
2 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 2/1, Barrikadnaia st., Moscow, 125993, Russian Federation;
3 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 1, Ostrovitianova st., Moscow, 117997, Russian Federation
*ivnechushkina@mail.ru